Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer

被引:48
作者
Ikeda, I
Miura, T
Kondo, I
机构
[1] Kanagawa Cancer Center, Division of Urology, Asahi-ku, Yokohama 241
来源
BRITISH JOURNAL OF UROLOGY | 1996年 / 77卷 / 01期
关键词
prostate cancer; bone metastases; pyridinoline; deoxypyridinoline;
D O I
10.1046/j.1464-410X.1996.82817.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To determine whether the urinary excretion of urinary pyridinoline (Py) and deoxypyridinoline (dPy) serve as markers to evaluate the activity of bone metastases and the response to endocrine therapy, by determining the relationship between the excretion of these compounds and the activity of bone metastases in patients with prostate cancer. Patients and methods Urine specimens were obtained from 15 patients with benign prostatic hypertrophy (BPH), 17 with carcinoma clinically confined to the prostate and 26 with prostate cancer and bone metastases, Among the patients with prostate cancer and bone metastases, 15 were new or reactivated cases and the 11 others were well controlled by hormonal therapy. Urinary Py and dPy were analysed using high-pressure liquid chromatography. Results Patient with new or reactivated prostate cancer with bone metastases had a higher urinary excretion of Py and dPy than did the patients with BPH, patients with prostate cancer and no bone metastases and patients with prostate cancer and bone metastases well controlled with hormonal therapy. Urinary levels of these compounds correlated with the extent of bone metastases in new and rt activated cases, Initial high levels of these cross-linked compounds in patients with multiple bone metastases fell as the prostate cancer was controlled by hormonal therapy. Conclusion Urinary excretion of Py and Dpy appears to be a useful marker for evaluating the activity of bone metastases and their response to hormonal treatment in prostate cancer.
引用
收藏
页码:102 / 106
页数:5
相关论文
共 16 条
[1]   URINARY PYRIDINIUM CROSS-LINKS AS MARKERS OF BONE-RESORPTION IN TUMOR-ASSOCIATED HYPERCALCEMIA [J].
BODY, JJ ;
DELMAS, PD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) :471-475
[2]   HYDROXYPYRIDINIUM CROSSLINKS OF SKELETAL COLLAGENS - THEIR MEASUREMENT, PROPERTIES AND A PROPOSED PATHWAY OF FORMATION [J].
EYRE, DR ;
OGUCHI, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1980, 92 (02) :403-410
[3]   STRUCTURE OF PYRIDINOLINE, A COLLAGEN CROSSLINK [J].
FUJIMOTO, D ;
MORIGUCHI, T ;
ISHIDA, T ;
HAYASHI, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1978, 84 (01) :52-57
[4]   ANALYSIS OF PYRIDINOLINE, A CROSS-LINKING COMPOUND OF COLLAGEN-FIBERS, IN HUMAN-URINE [J].
FUJIMOTO, D ;
SUZUKI, M ;
UCHIYAMA, A ;
MIYAMOTO, S ;
INOUE, T .
JOURNAL OF BIOCHEMISTRY, 1983, 94 (04) :1133-1136
[5]   RAPID ASSAY FOR HARD TISSUE COLLAGEN CROSS-LINKS USING ISOCRATIC ION-PAIR REVERSED-PHASE LIQUID-CHROMATOGRAPHY [J].
JAMES, IT ;
PERRETT, D ;
THOMPSON, PW .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 525 (01) :43-57
[6]   COLLAGEN CROSS-LINK METABOLITES IN URINE AS MARKERS OF BONE METASTASES IN PROSTATIC-CARCINOMA [J].
MIYAMOTO, KK ;
MCSHERRY, SA ;
ROBINS, SP ;
BESTERMAN, JM ;
MOHLER, JL .
JOURNAL OF UROLOGY, 1994, 151 (04) :909-913
[7]   A NOVEL FLUOR IN INSOLUBLE COLLAGEN - A CROSSLINKING MOIETY IN COLLAGEN MOLECULE [J].
OGAWA, T ;
ONO, T ;
TSUDA, M ;
KAWANISHI, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1982, 107 (04) :1252-1257
[8]   PYRIDINIUM CROSS-LINKS AS MARKERS OF BONE-RESORPTION IN PATIENTS WITH BREAST-CANCER [J].
PATERSON, CR ;
ROBINS, SP ;
HOROBIN, JM ;
PREECE, PE ;
CUSCHIERI, A .
BRITISH JOURNAL OF CANCER, 1991, 64 (05) :884-886
[9]   PYRIDINIUM CROSS-LINKS OF BONE-COLLAGEN AND THEIR LOCATION IN PEPTIDES ISOLATED FROM RAT FEMUR [J].
ROBINS, SP ;
DUNCAN, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 914 (03) :233-239
[10]  
SEGREST JP, 1982, METHOD ENZYMOL, V82, P398